Ken Griffin
SLNO

Ken Griffin’s Soleno Therapeutics SLNO Stock Holding History

Ken Griffin’s Portfolio SLNO Stock Details SLNO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$12.9M Buy
386,545
+77,715
+25% +$3.05M ﹤0.01% 2881
2025
Q4 		$14.3M Sell
308,830
-141,296
-31% -$7.75M ﹤0.01% 2762
2025
Q3 		$30.4M Sell
450,126
-1,055,035
-70% -$78.2M ﹤0.01% 1861
2025
Q2 		$126M Sell
1,505,161
-70,883
-4% -$5.31M 0.02% 621
2025
Q1 		$113M Buy
1,576,044
+603,634
+62% +$29.4M 0.02% 629
2024
Q4 		$43.7M Buy
972,410
+950,670
+4,373% +$49.3M 0.01% 1399
2024
Q3 		$1.1M Buy
21,740
+13,613
+168% +$652K ﹤0.01% 6691
2024
Q2 		$332K Buy
+8,127
New +$344K ﹤0.01% 8933
2023
Q4 		– Sell
-40,625
Closed -$1.16M – 15167
2023
Q3 		$1.2M Buy
+40,625
New +$246K ﹤0.01% 6201
2022
Q3 		– Sell
-19,687
Closed -$55K – 13528
2022
Q2 		$55K Buy
19,687
+10,045
+104% +$27.8K ﹤0.01% 11872
2022
Q1 		$32K Sell
9,642
-350
-4% -$1.81K ﹤0.01% 13073
2021
Q4 		$61K Sell
9,992
-538
-5% -$5.64K ﹤0.01% 13134
2021
Q3 		$146K Buy
10,530
+871
+9% +$12.1K ﹤0.01% 12411
2021
Q2 		$165K Buy
9,659
+5,466
+130% +$92.4K ﹤0.01% 12395
2021
Q1 		$79K Buy
4,193
+2,837
+209% +$91.4K ﹤0.01% 12636
2020
Q4 		$39K Buy
1,356
+382
+39% +$11K ﹤0.01% 10658
2020
Q3 		$37K Buy
+974
New +$28.5K ﹤0.01% 9702
2019
Q2 		– Sell
-1,195
Closed -$37K – 9785
2019
Q1 		$37K Buy
+1,195
New +$31.8K ﹤0.01% 8930
2018
Q3 		– Sell
-862
Closed -$30K – 9648
2018
Q2 		$30K Buy
+862
New +$25.3K ﹤0.01% 8567
2017
Q4 		– Sell
-365
Closed -$14K – 8407
2017
Q3 		$14K Buy
+365
New +$14.4K ﹤0.01% 7414
2017
Q2 		– Sell
-327
Closed -$17K – 8014
2017
Q1 		$17K Buy
+327
New +$19.3K ﹤0.01% 7289
2016
Q4 		– Sell
-317
Closed -$23K – 7794
2016
Q3 		$23K Buy
+317
New +$24K ﹤0.01% 7009
2015
Q3 		– Sell
-140
Closed -$30K – 9200
2015
Q2 		$30K Buy
+140
New +$53.8K ﹤0.01% 7964

Other funds holding SLNO

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
KCM
Khrom Capital Management Miami Beach, Florida $1.09B AUM 14.82% 1-Year Est. Return

Ken Griffin's SLNO Position: Q1 2026 in Review

Ken Griffin increased its Soleno Therapeutics (SLNO) stake by 25% in Q1 2026, buying an estimated $3.05M and bringing the position to 386,545 shares worth $12.9M. The position accounts for ﹤0.01% of the portfolio, ranked #2881.

Ken Griffin first reported a position in SLNO in Q2 2015 and has held it in 23 quarters since. The position peaked at $126M in Q2 2025. 225 funds tracked by Wall St. Rank hold SLNO as of Q1 2026.

  • Ken Griffin held 386,545 shares of Soleno Therapeutics worth $12.9M as of Q1 2026.
  • Ken Griffin bought 77,715 Soleno Therapeutics shares in Q1 2026, an estimated $3.05M.
  • Soleno Therapeutics made up ﹤0.01% of Ken Griffin's portfolio in Q1 2026, its #2881 holding.
  • Ken Griffin first reported a position in Soleno Therapeutics in Q2 2015 and has held it in 23 quarters since.
  • Ken Griffin's Soleno Therapeutics position peaked at $126M in Q2 2025.
  • 225 funds tracked by Wall St. Rank held Soleno Therapeutics as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.